First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. in Leukemia & lymphoma / Leuk Lymphoma. 2018 Jul;59(7):1523-1538. doi: 10.1080/10428194.2017.1379074. Epub 2017 Oct 3.

2018
AOU San Luigi di Orbassano